Iwona Wybranska

Prof. Dr. Iwona Wybranska

Clinical Biochemistry, Jagiellonian University Medical College (JU MC), Kraków, Małopolskie, Poland
orcid

Research Focus & Metrics

Academic Career Length

44Years (1983-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2012 in Archives of Medical Research
Verified
Journal Article
Closed access
Ewa Łucja StępieńEwa Łucja Stępień
Ewa Łucja Stępień
ESElżbieta Stankiewicz
Elżbieta Stankiewicz
JZJarosław Zalewski
Jarosław Zalewski
JGJacek Godlewski
Jacek Godlewski
KŻKrzysztof Żmudka
Krzysztof Żmudka
IWIwona Wybranska
Iwona Wybranska

1 September 2010 in Pharmacological Reports
Verified
Journal Article
Closed access
BZBarbara Zapała
Barbara Zapała
ŁKŁukasz Kaczyński
Łukasz Kaczyński
BKBeata Kieć-Wilk
Beata Kieć-Wilk
TSTeresa Staszel
Teresa Staszel
AKAnna Knapp
Anna Knapp
ADAldona Dembińska-Kieć
Aldona Dembińska-Kieć

1 January 2011 in Atherosclerosis
Verified
Journal Article
Closed access
JDJavier Delgado-Lista
Javier Delgado-Lista
PPPABLO PEREZ-MARTINEZ
PABLO PEREZ-MARTINEZ
AGA. García-Rios
A. García-Rios
Catherine PhillipsCatherine Phillips
Catherine Phillips
CWC.M. Williams
C.M. Williams
JLJosé López-Miranda
José López-Miranda

1 October 2007 in British Journal of Nutrition
Verified
Journal Article
Closed access
PDF file
RERuan Elliott
Ruan Elliott
Catalina PicóCatalina Picó
Catalina Picó
YDYvonne Dommels
Yvonne Dommels
IWIwona Wybranska
Iwona Wybranska
JHJohn Hesketh
John Hesketh
JKJaap Keijer
Jaap Keijer
To be able to perform a comprehensive and rigorous benefit-risk analysis of individual food components, and of foods, a number of fundamental questions need to be addressed first. These include whether it is feasible to detect all relevant biological effects of foods and individual food components, how such effects can confidently be categorised into benefits and risks in relation to health and, for that matter, how health can be quantified. This article examines the last of these issues, focusing upon concepts for the development of new biomarkers of health. Clearly, there is scope for refinement of classical biomarkers so that they may be used to detect even earlier signs of disease, but this approach defines health solely as the absence of detectable disease or disease risk. We suggest that the health of a biological system may better be reflected by its ability to withstand and manage relevant physiological challenges so that homeostasis is maintained. We discuss the potential for expanding the range of current challenge tests for use in conjunction with functional genomic technologies to develop new types of biomarkers of health.

1 June 2006 in British Journal of Nutrition
Verified
Journal Article
Closed access
PDF file
JHJohn Hesketh
John Hesketh
IWIwona Wybranska
Iwona Wybranska
YDYvonne Dommels
Yvonne Dommels
MKMaria King
Maria King
RERuan Elliott
Ruan Elliott
JKJaap Keijer
Jaap Keijer
Individuals respond differently to nutrients and foods. This is reflected in different levels of benefits and risks at the same intake of a nutrient and, consequently, different ‘windows of benefit’ in terms of nutrient intake. This has led recently to the concept of ‘personalised nutrition’. Genetic factors such as single nucleotide polymorphisms may be one source of this inter-individual variation in benefit–risk response to nutrients. In 2004 a European Union-funded network of excellence in the area of nutrigenomics (European Nutrigenomics Organisation; NuGO) organised a workshop on the role of nutrient–gene interactions in determining benefit–risk of nutrients and diet. The major issues discussed at theworkshop are presented in the present paper and highlighted with examples from the presentations. The overall consensus was that although genetics provides a new vision where genetic information could in the future be used to provide knowledge on disease predisposition and nutritionalrequirements, such a goal is still far off and much more research is required before we can reliably include genetic factors in the risk–benefit assessment of nutrients and diets.

4 August 2015 in Experimental and Clinical Endocrinology & Diabetes
Verified
Journal Article
Closed access
PDF file
MSM. Szopa
M. Szopa
JWJ. Wolkow
J. Wolkow
BMB. Matejko
B. Matejko
JSJ. Skupien
J. Skupien
TKT. Klupa
T. Klupa
MMM. T. Malecki
M. T. Malecki
We aimed to assess the prevalence of diabetic retinopathy (DR) in adult patients with GCK-MODY and HNF1A-MODY in Poland and to identify biochemical and clinical risk factors associated with its occurrence. We examined 74 GCK mutation carriers, 51 with diabetes and 23 with prediabetes, respectively, and 63 patients with HNF1A-MODY. Retinal photographs, 12 for each patient, were done by a fundus camera. Signs of DR were graded according to the DR disease severity scale. Statistical tests were performed to assess differences between the groups and logistic regression was done for the association with DR. The mean age at examination was 34.5±14.8 and 39.9±15.2 in the GCK-MODY and HNF1A-MODY groups, respectively. Mild nonproliferative DR (NPDR) was found in one patient with the GCK mutation and likely concomitant type 1 diabetes, whereas DR was diagnosed in 15 HNF1A-MODY patients: 9 with proliferative, 3 with moderate NPDR and 2 with mild NPDR. In univariate logistic regression analysis in the HNF1A-MODY group, significant results were found for diabetes duration, fasting glycemia, HbA1c, arterial hypertension, age at the examination, and eGFR. The strongest independent predictors of DR in HNF1A-MODY were markers of glucose control: HbA1c (OR: 2.05, CL%95: 1.2–3.83, p=0.01) and glucose (p=0.006, OR: 1.40, CL%95: 1.12–1.83) analyzed in 2 separated models. Additionally, arterial hypertension independently predicted DR (OR: 9.06, CL%95: 1.19–98.99, p=0.04) in the model with HbA1c as glycaemic control marker. In conclusion, DR of any degree was not present in our GCK-MODY group, while in spite of young age almost every fourth subject with HNF1A-MODY showed signs of this complication.